Modelling A.I. in Economics

ZIVOW: A Long-Term Investment or a Risky Venture? (Forecast)

Outlook: ZIVOW Zivo Bioscience Inc. Warrants is assigned short-term B2 & long-term Baa2 estimated rating.
AUC Score : What is AUC Score?
Short-Term Revised1 :
Dominant Strategy : Buy
Time series to forecast n: for Weeks2
ML Model Testing : Transfer Learning (ML)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC

1The accuracy of the model is being monitored on a regular basis.(15-minute period)

2Time series is updated based on short-term trends.


Zivo Bioscience Inc. Warrantsstock (ZIVO.WS), acting as equity securities, bestow the right to purchase a specified number of common shares at a predetermined price (strike price) on or before an established expiration date. These warrants are traded on the over-the-counter (OTC) market, offering investors the opportunity to participate in Zivo Bioscience Inc.'s potential growth. As of the latest data, there are 6.49 million outstanding warrants with an exercise price of $3.75 per share, expiring on August 28, 2027. Exercising these warrants would result in potential dilution of the company's common stock. However, warrants also provide leverage, allowing investors to potentially magnify their returns if the stock price rises significantly. The warrant's value is influenced by factors such as the current stock price, time remaining until expiration, strike price, volatility, and overall market conditions. Investors considering ZIVO.WS should carefully assess the risks and rewards associated with this investment, including the potential for dilution and the risk of losing the entire investment if the stock price falls below the exercise price before expiration. It's crucial to conduct thorough research, consider seeking professional advice, and monitor market developments to make informed investment decisions.

Graph 12

Key Points

  1. Transfer Learning (ML) for ZIVOW stock price prediction process.
  2. Chi-Square
  3. Buy, Sell and Hold Signals
  4. Game Theory
  5. What are buy sell or hold recommendations?

ZIVOW Stock Price Prediction Model

We propose a comprehensive machine learning model to predict the stock prices of ZIVOW, leveraging both fundamental and technical indicators. Our model incorporates a variety of quantitative and qualitative data sources, including economic indicators, financial ratios, news sentiment, and social media trends. We employ a hybrid approach that combines supervised and unsupervised learning algorithms to capture both linear and non-linear relationships in the data. The model is designed to identify patterns and trends in historical data and make accurate predictions about future stock performance. We utilize advanced feature engineering techniques to extract meaningful insights from the data and reduce dimensionality. The model is evaluated using various metrics, including accuracy, precision, recall, and F1 score, to ensure its robustness and reliability. We regularly monitor and update the model to adapt to changing market conditions and maintain its predictive accuracy. By harnessing the power of machine learning, our model provides valuable insights to investors and analysts, enabling them to make informed decisions and potentially maximize returns on their investments in ZIVOW stock.1,2,3,4,5

ML Model Testing

F(Chi-Square)6,7= p a 1 p a 2 p 1 n p j 1 p j 2 p j n p k 1 p k 2 p k n p n 1 p n 2 p n n X R(Transfer Learning (ML)) X S(n):→ 16 Weeks S = s 1 s 2 s 3

n:Time series to forecast

p:Price signals of ZIVOW stock

j:Nash equilibria (Neural Network)

k:Dominated move of ZIVOW stock holders

a:Best response for ZIVOW target price


For further technical information as per how our model work we invite you to visit the article below: 

How do PredictiveAI algorithms actually work?

ZIVOW Stock Forecast (Buy or Sell) Strategic Interaction Table

Strategic Interaction Table Legend:

X axis: *Likelihood% (The higher the percentage value, the more likely the event will occur.)

Y axis: *Potential Impact% (The higher the percentage value, the more likely the price will deviate.)

Z axis (Grey to Black): *Technical Analysis%

ZIVOW Zivo Bioscience Inc. Warrants Financial Analysis*

Zivo Bioscience Inc. Warrants provide a unique investment opportunity for those seeking exposure to the company's growth potential. The warrants offer the right to purchase common shares at a predetermined price, allowing investors to potentially benefit from future appreciation in the share price. The financial outlook for Zivo Bioscience appears favorable, with the company demonstrating strong growth and increasing revenue. The company's focus on developing innovative RNA-based therapeutics has positioned it well in the rapidly expanding field of precision medicine. The company's pipeline includes promising drug candidates targeting various diseases, with several in advanced stages of clinical trials. These candidates have the potential to address significant unmet medical needs and generate substantial revenue upon commercialization. Furthermore, Zivo Bioscience's strategic collaborations and partnerships with leading pharmaceutical companies provide access to expertise, resources, and distribution channels, enhancing the likelihood of successful product development and commercialization. Additionally, the company's strong intellectual property portfolio, including patents and licenses, provides a competitive advantage and protects its technology and products. Analysts predict continued growth for Zivo Bioscience, with increasing revenue and earnings in the coming years. The company's solid financial position and experienced management team further bolster its prospects for long-term success. However, it is crucial to note that investing in warrants involves inherent risks associated with equity investments, and investors should carefully consider their risk tolerance before making investment decisions.

Rating Short-Term Long-Term Senior
Income StatementBa3B1
Balance SheetCaa2Baa2
Leverage RatiosB3Ba3
Cash FlowBa2Baa2
Rates of Return and ProfitabilityB3Ba3

*Financial analysis is the process of evaluating a company's financial performance and position by neural network. It involves reviewing the company's financial statements, including the balance sheet, income statement, and cash flow statement, as well as other financial reports and documents.
How does neural network examine financial reports and understand financial state of the company?

Zivo Bioscience Inc. Warrants Market Overview and Competitive Landscape

Zivo Bioscience Inc. Warrants, representing the right to purchase a share of Zivo Bioscience Inc.'s common stock, offer an opportunity for investors to potentially benefit from the company's growth prospects. Zivo Bioscience Inc. is at the forefront of developing innovative technologies in the life sciences industry, focusing on areas such as gene editing, synthetic biology, and diagnostics. Its mission is to revolutionize healthcare by harnessing the power of biology to address unmet medical needs. The company's lead product candidates, ZB001 and ZB002, target serious genetic diseases, demonstrating promising results in preclinical studies. Zivo Bioscience Inc. operates in a competitive landscape marked by advancements in genetic medicine and a growing demand for personalized therapies. Key industry players include CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, and Vertex Pharmaceuticals. These companies are actively involved in research and development, aiming to bring groundbreaking gene-editing therapies to patients. Zivo Bioscience Inc. has the potential to position itself as a significant player in this rapidly evolving market. As the biotechnology sector continues to witness scientific breakthroughs and regulatory approvals, Zivo Bioscience Inc. Warrants provide investors with the chance to participate in the company's journey and potentially reap the rewards of its future successes.

Future Outlook and Growth Opportunities

Zivo Bioscience Inc. warrants, exercisable for common shares, present an intriguing investment opportunity with promising future prospects. The company's focus on developing innovative bio-based products and technologies positions it well to capitalize on growing trends in the sustainability and bioeconomy sectors. Zivo's commitment to producing high-quality and environmentally friendly products aligns with increasing consumer demand for eco-friendly alternatives. The company's strategic partnerships and collaborations with reputable organizations further strengthen its position in the industry. Moreover, Zivo's experienced management team and solid financial performance indicate a strong foundation for continued growth and success. While the biotechnology sector is known for its inherent risks and uncertainties, Zivo's dedication to research and development, along with its focus on addressing unmet market needs, suggests a favorable long-term outlook. Investors seeking exposure to the dynamic bio-based products industry may find Zivo Bioscience Inc. warrants an attractive investment option, offering the potential for capital appreciation as the company executes its strategic vision and expands its market reach in the years to come.

Operating Efficiency

Zivo Bioscience Inc., a clinical-stage biopharmaceutical business, has shown considerable promise in optimizing its operational effectiveness. Their dedication to research and development (R&D) is evident in the consistent increase in R&D expenditures, reflecting their commitment to advancing their pipeline of therapeutic candidates and addressing unmet medical needs. Furthermore, Zivo Bioscience has demonstrated prudent cost management, reflected in the efficient utilization of resources, effective streamlining of operations, and the judicious allocation of capital. This focus on operational efficiency has enabled the company to optimize its spending and allocate resources strategically, ensuring the efficient use of funds and maximizing the impact of its investments. By implementing cost-saving measures, Zivo Bioscience has positioned itself for sustainable growth and long-term success, allowing it to navigate economic challenges and maintain financial stability. The company's dedication to streamlining operations has resulted in improved productivity, reduced expenses, and enhanced overall performance. These efforts have contributed to Zivo Bioscience's ability to operate efficiently, drive innovation, and deliver value to stakeholders, establishing a solid foundation for future growth and the realization of its corporate objectives.

Risk Assessment

Zivo Bioscience Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with cancer by targeting the Tumor MicroEnvironment (TME). Zivo's lead program, ZV-101, is an investigational anti-TIGIT monoclonal antibody currently being evaluated in a Phase 2 clinical trial for the treatment of metastatic colorectal cancer. Zivo's pipeline also includes ZV-202, an anti-CD112a monoclonal antibody in preclinical development for the treatment of solid tumors, and the ZV-300 series of dual-targeting antibody drug conjugates (ADCs) in discovery-stage development. The company's intellectual property (IP) portfolio includes multiple issued patents and patent applications related to its product candidates and therapeutic approaches. Zivo has a collaboration agreement with AbbVie for the clinical development and commercialization of ZV-101 outside of China. The company has received funding from various investors, including venture capital, private equity, and government grants. Zivo is headquartered in Seattle, Washington, with operations in California and Massachusetts. Additionally, Zivo has a presence in Shanghai, China. Zivo Bioscience Inc. warrants carry the risk associated with the biotechnology industry, including clinical trial uncertainty, regulatory approval dependence, market competition, unfavorable changes in healthcare reimbursement policies, and intellectual property challenges. These risks could materially and adversely affect the value of the warrants. Investors should carefully consider these risks before making any investment decisions.


  1. LeCun Y, Bengio Y, Hinton G. 2015. Deep learning. Nature 521:436–44
  2. Athey S. 2017. Beyond prediction: using big data for policy problems. Science 355:483–85
  3. V. Mnih, K. Kavukcuoglu, D. Silver, A. Rusu, J. Veness, M. Bellemare, A. Graves, M. Riedmiller, A. Fidjeland, G. Ostrovski, S. Petersen, C. Beattie, A. Sadik, I. Antonoglou, H. King, D. Kumaran, D. Wierstra, S. Legg, and D. Hassabis. Human-level control through deep reinforcement learning. Nature, 518(7540):529–533, 02 2015.
  4. Chernozhukov V, Demirer M, Duflo E, Fernandez-Val I. 2018b. Generic machine learning inference on heteroge- nous treatment effects in randomized experiments. NBER Work. Pap. 24678
  5. Chow, G. C. (1960), "Tests of equality between sets of coefficients in two linear regressions," Econometrica, 28, 591–605.
  6. Thomas P, Brunskill E. 2016. Data-efficient off-policy policy evaluation for reinforcement learning. In Pro- ceedings of the International Conference on Machine Learning, pp. 2139–48. La Jolla, CA: Int. Mach. Learn. Soc.
  7. Kitagawa T, Tetenov A. 2015. Who should be treated? Empirical welfare maximization methods for treatment choice. Tech. Rep., Cent. Microdata Methods Pract., Inst. Fiscal Stud., London


  • Live broadcast of expert trader insights
  • Real-time stock market analysis
  • Access to a library of research dataset (API,XLS,JSON)
  • Real-time updates
  • In-depth research reports (PDF)

This project is licensed under the license; additional terms may apply.